AIMC Topic: Radiation-Sensitizing Agents

Clear Filters Showing 1 to 2 of 2 articles

Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study.

Radiation oncology (London, England) Feb 10, 2022
BACKGROUND: Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy (GPT) for non-metastatic, locally advanced pancreatic cancer (LAPC) remain unclear. This study aimed to determine the factors associated with long-te...
Humans Retrospective Studies Female Aged Aged, 80 and over Adult Survival Rate Male Middle Aged Time Factors Pancreatic Neoplasms Neoplasm Staging Combined Modality Therapy Antimetabolites, Antineoplastic Deoxycytidine Gemcitabine Proton Therapy Radiation-Sensitizing Agents
View on PubMed DOI

Doxorubicin enhances (131)I-rituximab induced cell death in Raji cells.

Journal of cancer research and therapeutics Jan 1, 2015
AIM: There are various therapeutic modalities of treatment for non-Hodgkin's lymphoma, but with certain limitations, hence, investigating the scope of combined therapeutic approach.
Humans RNA, Messenger Cell Proliferation Signal Transduction Antineoplastic Combined Chemotherapy Protocols Apoptosis Blotting, Western Flow Cytometry Radiopharmaceuticals Doxorubicin Iodine Radioisotopes Drug Synergism Tumor Cells, Cultured Rituximab Poly(ADP-ribose) Polymerases Burkitt Lymphoma Radiation-Sensitizing Agents
View on PubMed DOI
Popular Topics
Recent Journals